{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Count of participants with Toxicities maximum grade greater than or equal to grade 3","groups":[{"description":"Patients receive gemcitabine IV over 30 minutes followed by docetaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.\n\nGemcitabine Hydrochloride: Given IV\n\nDocetaxel: Given IV","id":"OG000","title":"Treatment (Gemcitabine Hydrochloride, Docetaxel)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and Treated patients","reportingStatus":"POSTED","timeFrame":"Assessed every 28 days (28 days=1 cycle) while on study treatment, 30 days after the last cycle of treatment, and up to 5 years in follow-up","title":"Incidence of Adverse Effects That Are Grade 3 or Greater as Assessed by Common Terminology Criteria for Adverse Events Version 3.0","type":"PRIMARY","unitOfMeasure":"Participants"}